AU2008261252B2 - Diagnostic method - Google Patents

Diagnostic method Download PDF

Info

Publication number
AU2008261252B2
AU2008261252B2 AU2008261252A AU2008261252A AU2008261252B2 AU 2008261252 B2 AU2008261252 B2 AU 2008261252B2 AU 2008261252 A AU2008261252 A AU 2008261252A AU 2008261252 A AU2008261252 A AU 2008261252A AU 2008261252 B2 AU2008261252 B2 AU 2008261252B2
Authority
AU
Australia
Prior art keywords
hbp
individual
risk
severe sepsis
wbc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008261252A
Other languages
English (en)
Other versions
AU2008261252A1 (en
Inventor
Per Akesson
Lars Bjorck
Bertil Christensson
Heiko Herwald
Adam Linder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hansa Biopharma AB
Original Assignee
Hansa Biopharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38331957&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2008261252(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hansa Biopharma AB filed Critical Hansa Biopharma AB
Publication of AU2008261252A1 publication Critical patent/AU2008261252A1/en
Application granted granted Critical
Publication of AU2008261252B2 publication Critical patent/AU2008261252B2/en
Assigned to Hansa Biopharma AB reassignment Hansa Biopharma AB Request to Amend Deed and Register Assignors: HANSA MEDICAL AB
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2008261252A 2007-06-12 2008-06-12 Diagnostic method Active AU2008261252B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0711327.7 2007-06-12
GBGB0711327.7A GB0711327D0 (en) 2007-06-12 2007-06-12 Diagnostic method
PCT/EP2008/004743 WO2008151808A1 (en) 2007-06-12 2008-06-12 Diagnostic method

Publications (2)

Publication Number Publication Date
AU2008261252A1 AU2008261252A1 (en) 2008-12-18
AU2008261252B2 true AU2008261252B2 (en) 2013-03-14

Family

ID=38331957

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008261252A Active AU2008261252B2 (en) 2007-06-12 2008-06-12 Diagnostic method

Country Status (16)

Country Link
US (3) US8518648B2 (enExample)
EP (1) EP2129391B1 (enExample)
JP (1) JP5166522B2 (enExample)
KR (1) KR101563997B1 (enExample)
CN (2) CN103543271A (enExample)
AT (1) ATE548050T1 (enExample)
AU (1) AU2008261252B2 (enExample)
BR (1) BRPI0812875B8 (enExample)
CA (1) CA2690067C (enExample)
DK (1) DK2129391T3 (enExample)
ES (1) ES2380875T3 (enExample)
GB (1) GB0711327D0 (enExample)
PL (1) PL2129391T3 (enExample)
PT (1) PT2129391E (enExample)
SI (1) SI2129391T1 (enExample)
WO (1) WO2008151808A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0711327D0 (en) 2007-06-12 2007-07-25 Hansa Medical Ab Diagnostic method
US20100240049A1 (en) 2009-01-16 2010-09-23 Cepheid Methods of Detecting Cervical Cancer
JP5488885B2 (ja) * 2009-10-28 2014-05-14 国立大学法人 東京大学 感染症の疾患マーカー
GB201016161D0 (en) * 2010-09-24 2010-11-10 Hansa Medical Ab Diagnostic method
AU2011334548B2 (en) * 2010-11-26 2016-06-09 Immunexpress Pty Ltd Diagnostic and/or screening agents and uses therefor
GB201102108D0 (en) * 2011-02-07 2011-03-23 Hansa Medical Ab Diagnostic method
AU2012308365A1 (en) * 2011-09-16 2014-04-24 Cepheid Methods of detecting sepsis
US10260111B1 (en) 2014-01-20 2019-04-16 Brett Eric Etchebarne Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample
US10761093B2 (en) 2014-10-09 2020-09-01 Texas Tech University System Microdevice for cell separation utilizing activation phenotype
CN109541235A (zh) * 2018-08-19 2019-03-29 重庆早柒天生物科技股份有限公司 肝素结合蛋白和降钙素原二联检测试剂盒及其制备方法
US20220178932A1 (en) 2019-04-24 2022-06-09 Japanese Foundation For Cancer Research Cancer detection method and detection reagent
CN111208305B (zh) * 2020-02-16 2023-04-25 重庆翼锋生物科技有限公司 Hbp和pct在败血症诊断试剂制备中的用途
CN111951963B (zh) 2020-07-30 2022-09-02 中翰盛泰生物技术股份有限公司 Hbp在covid-19患者的预后风险预警中的应用
US20240230674A1 (en) * 2021-04-30 2024-07-11 Roche Diagnostics Operations, Inc. Strem1 marker panels for early detection of sepsis
JP2024516680A (ja) * 2021-04-30 2024-04-16 エフ． ホフマン－ラ ロシュ アーゲー 敗血症の早期検出用のｉｌ６マーカーパネル
EP4330685A2 (en) * 2021-04-30 2024-03-06 Roche Diagnostics GmbH Ngal marker panels for early detection of sepsis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076695A1 (en) * 2003-02-24 2004-09-10 Gtc Biotherapeutics, Inc. Methods of tangential flow filtration and an apparatus therefore
WO2005028512A1 (en) * 2003-09-19 2005-03-31 Leukotech A/S Pro-inflammatory and anti-inflammatory antibodies against the heparin-binding protein (hbp)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627262A (en) 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
US5962241A (en) * 1989-07-28 1999-10-05 The University Of Arizona Monoclonal antibody detection of proteins on sperm related to fertility
US5314804A (en) * 1992-03-24 1994-05-24 Serim Research Corporation Test for Helicobacter pylori
HU221638B1 (hu) 1994-04-21 2002-12-28 Leukotech A/S Heparinkötő fehérje alkalmazása szepszis kezelésére szolgáló gyógyszer előállítására
US5976536A (en) 1995-08-09 1999-11-02 Emory University Neisseria mutants, lipooligosaccharides and immunogenic compositions
US5778895A (en) 1997-01-29 1998-07-14 Uab Research Foundation Method of discriminating bacterial from aseptic meningitis
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7655480B2 (en) 2002-03-08 2010-02-02 The Board Of Regents Of The University Of Oklahoma Method for predicting sepsis or an acute infectious inflammatory response
AU2003220034A1 (en) 2002-03-08 2003-09-22 Heloise, Anne, Pereira, Ph. D. An early detection marker for chronic inflammatory associated diseases
WO2004016653A2 (en) 2002-08-15 2004-02-26 Leukotech A/S Bactericidal, anti-apoptotic, pro-inflammatory and anti-inflammatory peptides of heparin-binding protein (hbp) or human neutrophil elastase
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
WO2004112713A2 (en) 2003-06-20 2004-12-29 Royer Biomedical, Inc. Drug polymer complexes
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
JP2008538007A (ja) * 2005-04-15 2008-10-02 ベクトン，ディッキンソン アンド カンパニー 敗血症の診断
CA2624569A1 (en) 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
FR2894675B1 (fr) 2005-12-14 2008-06-27 Assist Publ Hopitaux De Paris Distinction des meningites bacteriennes et virales
GB0711327D0 (en) 2007-06-12 2007-07-25 Hansa Medical Ab Diagnostic method
GB201016161D0 (en) 2010-09-24 2010-11-10 Hansa Medical Ab Diagnostic method
GB201102108D0 (en) 2011-02-07 2011-03-23 Hansa Medical Ab Diagnostic method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076695A1 (en) * 2003-02-24 2004-09-10 Gtc Biotherapeutics, Inc. Methods of tangential flow filtration and an apparatus therefore
WO2005028512A1 (en) * 2003-09-19 2005-03-31 Leukotech A/S Pro-inflammatory and anti-inflammatory antibodies against the heparin-binding protein (hbp)

Also Published As

Publication number Publication date
AU2008261252A1 (en) 2008-12-18
PT2129391E (pt) 2012-06-06
SI2129391T1 (sl) 2012-07-31
PL2129391T3 (pl) 2012-09-28
CA2690067C (en) 2023-09-19
ES2380875T3 (es) 2012-05-21
US20140187503A1 (en) 2014-07-03
CN101687023A (zh) 2010-03-31
BRPI0812875A2 (pt) 2014-12-09
EP2129391A1 (en) 2009-12-09
BRPI0812875B1 (pt) 2017-12-05
DK2129391T3 (da) 2012-06-11
US8518648B2 (en) 2013-08-27
CN103543271A (zh) 2014-01-29
GB0711327D0 (en) 2007-07-25
US9784741B2 (en) 2017-10-10
US20100305185A1 (en) 2010-12-02
KR20100021578A (ko) 2010-02-25
EP2129391B1 (en) 2012-03-07
CA2690067A1 (en) 2008-12-18
KR101563997B1 (ko) 2015-10-28
WO2008151808A1 (en) 2008-12-18
CN101687023B (zh) 2016-04-20
JP2010529468A (ja) 2010-08-26
BRPI0812875B8 (pt) 2022-07-12
ATE548050T1 (de) 2012-03-15
US20130252347A1 (en) 2013-09-26
JP5166522B2 (ja) 2013-03-21

Similar Documents

Publication Publication Date Title
CA2690067C (en) A diagnostic method by measuring the levels of heparin-binding protein
JP6772237B2 (ja) ブラジキニン媒介障害の評価および治療
US8021836B2 (en) Method of diagnosing infectious disease by measuring the level of soluble TREM-1 in a sample
Ruiz-Alvarez et al. Diagnostic efficacy and prognostic value of serum procalcitonin concentration in patients with suspected sepsis
JP2944721B2 (ja) エンドトキシンの測定剤
US9759720B2 (en) Diagnostic method for bacterial meningitis
EP2673646B1 (en) Diagnostic method for urinary tract infection
Komaru et al. Nephritis-associated plasmin receptor (NAPlr) positive glomerulonephritis caused by Aggregatibacter actinomycetemcomitans bacteremia: A case report
JP2004500568A (ja) 敗血症マーカーとしてのインター−アルファ−トリプシン
JP2019528239A (ja) 変形性関節症を診断するためのコムペプチドおよびそれに対する抗体
CN115975025B (zh) C反应蛋白（crp）检测试剂盒
US20240272178A1 (en) A method for predicting sepsis and septic shock
EP3311164B1 (en) Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
CN116063482B (zh) C反应蛋白(crp)尿液检测试剂盒
US20220357344A1 (en) Prognosis prediction method of idiopathic pulmonary fibrosis
US20120135425A1 (en) ELISA for Haptoglobin-Matrix Metalloproteinase 9 Complex as a Diagnostic Test for Conditions Including Acute Inflammation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: HANSA BIOPHARMA AB

Free format text: FORMER NAME(S): HANSA MEDICAL AB